Coegin Pharma AB (publ) ("Coegin Pharma" or "the Company") issued a total of 5,279,936 warrants of series TO3 ("Warrants") in connection with the Company's share issues earlier this year. Today, on 16 September 2024, the exercise period for the Warrants begins. One (1) Warrant entitles the holder to subscribe for one (1) new share in the Company. The subscription price per share through the exercise of the Warrants has been set at SEK 3.9 per share. The exercise period for the Warrants runs until 30 September 2024. Upon full exercise of all Warrants, Coegin Pharma will raise approximately MSEK 20.6  before transaction costs. The proceeds from the exercise of the Warrants, together with funds raised from the share issues earlier this year, are primarily intended for the Company's hair growth project, FOL005. The funds will be used for production, completion of regulatory processes, and strengthening the Company's position in ongoing partner discussions, in preparation for a planned product launch in 2025.

Summary of the Warrants' terms:

• The exercise period for the Warrants runs from 16 September 2024, until 30 September 2024.
• One (1) warrant of series TO3 entitles the holder to subscribe for one (1) new share in the Company.
• Trading in Warrants will continue until 26 September 2024. Warrants not exercised by 30 September 2024, will expire without value.
• Holders with nominee-registered Warrants must contact their nominee to exercise their Warrants and follow the nominee's instructions regarding subscription and payment. This should be done well before 30 September 2024, as processing times vary between nominees.
• Holders with directly registered Warrants must notify the exercise of Warrants by completing and submitting the subscription form, ensuring it reaches the issuing institute, Nordic Issuing, no later than 30 September 2024. The subscription form is available on the websites of the Company, Nordic Issuing, and Redeye AB.
• Upon full exercise of all Warrants, Coegin Pharma will raise approximately MSEK 20.6 before issuance costs.
• The subscription price of SEK 3.9 per new share has been determined in accordance with the terms of the Warrants, under which the subscription price per new share corresponds to seventy (70) percent of the volume-weighted average price (VWAP) of the Company's share on Nordic SME Sweden over a period of ten (10) trading days immediately preceding, and including, 13 September 2024, but no less than SEK 2 per share. Full terms of the Warrants are available on the Company's website, coeginpharma.com.

Increase in number of shares and share capital
Upon full exercise of all 5,279,936 Warrants, the share capital will increase by a maximum of SEK 2,639,968 to SEK 12,833,024 through the issuance of up to 5,279,936 shares, resulting in the total number of outstanding shares in the Company increasing from 20,386,112 to 25,666,048. Full exercise of the Warrants will result in dilution of approximately 21 percent.

Advisors
Redeye AB is the financial advisor in connection with the share issues. Lindahl Law Firm KB is the legal advisor to Coegin Pharma in connection with the share issues. Nordic Issuing AB is acting as the issuing institute in the share issues.

For further information, please contact:
Jens Eriksson, CEO
Email: info@coeginpharma.com
Phone: +46 72 221 24 21

This document is a translation of the original Swedish press release. In case of any discrepancies, the Swedish version shall prevail. 

About Coegin Pharma
Coegin Pharma is a Swedish biotech company with dermacosmetic innovations for hair growth and skin pigmentation, alongside groundbreaking drug candidates for the treatment of myocardial infarction and leukemia. Coegin is planning for the launch of its first product series for hair growth in 2025, followed by a skin pigmentation product in 2026.

Coegin Pharma's shares are listed on NGM Nordic SME and Börse Stuttgart, and the company has a registered office in Lund, Sweden.

For more information, please visit: coeginpharma.com/en

IMPORTANT INFORMATION
The information in this press release does not contain or constitute an offer to acquire, subscribe for, or otherwise trade in shares, warrants, or other securities of the Company. The invitation to the relevant persons to subscribe for units consisting of shares in the Company and Warrants was made solely through the memorandum published on 6 February 2024.

Attached files